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Abstract
Background: Despite broad advances in multimodal treatment of locally advanced breast cancer (LABC), 30 to
40% of patients develop loco-regional relapse. The aim of this study was to analyze in a retrospective manner the
effectiveness of concurrent chemo-radiotherapy (CCRTh) after neoadjuvant chemotherapy (NCT) in patients
with LABC.
Methods: One hundred twelve patients with LABC (stage IIB-IIIB) were treated with NCT (5-fluorouracil 500
mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2  (FAC), or doxorubicin 50 mg/m2  and
cyclophosphamide 500 mg/m2 (AC) IV in four 21-day courses) followed by CCRTh (60 Gy breast irradiation and
weekly mitomycin 5 mg/m2, 5-fluorouracil 500 mg/m2, and dexamethasone 16 mg, or cisplatin 30 mg/m2,
gemcitabine 100 mg/m2 and dexamethasone 16 mg), and 6–8 weeks later, surgery and two additional courses of
FAC, AC, or paclitaxel 90 mg/m2 weekly for 12 weeks, and in case of estrogen-receptor positive patients,
hormonal therapy.
Results: Stages IIB, IIIA and -B were 21.4, 42.9, and 35.7%, respectively. Pathological complete response (pCR)
in the breast was 42% (95% CI, 33.2–50.5%) and, 29.5% (95% CI, 21.4–37.5%) if including both the breast and the
axillary nodes. Multivariate analysis showed that the main determinant of pCR was negative estrogen-receptor
status (HR = 3.8; 95% CI, 1.5–9; p = 0.016). The 5-year disease-free survival (DFS) was 76.9% (95% CI, 68.2–
84.7%). No relationship between pCR and DFS was found. Multivariate analysis demonstrated that the main DFS
determinant was clinical stage (IIB and IIIA vs. IIIB, HR = 3.1; 95% CI, 1.02–9.74; p = 0.04). Only one patient had
local recurrence. Five-year overall survival was 84.2% (95% CI, 75–93.2%). The toxicity profile was acceptable.
Conclusion:  This non-conventional multimodal treatment has good loco-regional control for LABC.
Randomized clinical trials of preoperative CCRTh following chemotherapy, in patients with LABC are warranted.
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Background
Breast cancer is the second leading cause of cancer death
among women in developed countries and in Mexico
[1,2]. In Mexico, only a small percentage of women have
regular mammography screening; therefore the propor-
tion of patients with locally advanced disease at diagnosis
is high. In 2003, only 5–10% of newly diagnosed cases in
Mexico were clinical stages 0 or I [2]. In fact, nearly 70%
of breast cancer cases of patients seen at the Instituto
Nacional de Cancerología (INCan: a cancer-referral teach-
ing hospital for adult patients, located in Mexico City) are
stage IIB-IIIB, locally advanced breast cancer (LABC, 6th
edition of the AJCC Cancer Staging) [3,4].
Current treatment of LABC requires a combination of sys-
temic chemotherapy (CT), surgery, and radiotherapy (RT)
[5]. Between six and eight courses of anthracycline- and
taxane-based regimens administered sequentially or in
combination are now recommended, and CT should be
followed by segmental or modified radical mastectomy
for operable tumors. Patients with inoperable tumors
after maximal CT (i.e., taxane if initial therapy was anthra-
cycline-based) could proceed to definitive RT. Patients
treated with surgery should receive post-operative RT to
minimize the risk of local recurrence. In addition, women
with hormone-receptor-positive tumors should receive
hormonal therapy (HT) [5].
However, only 10–20% of patients with LABC achieve
clinical complete response, and 50–60%, partial response
[6-8]. Pathological complete response (pCR) rate in LABC
is poor, 8–12%, and often does not correlate with clinical
response [6,8-11]. Approximately, 30–40% of patients
with LABC develop loco-regional relapse (LRR) [8].
Despite improvements in local control rates and overall out-
comes with current therapy, 5-year survival for LABC
remains low (50% vs. 87% for stage I) [12]. Moreover, con-
current chemo-radiotherapy (CCRTh) with anthracycline
drugs is theoretically more toxic; therefore, in patients with
LABC, this treatment modality has not been widely used.
However, CCRTh has successfully improved both local con-
trol and overall survival (OS) in other cancers such as
esophageal, lung, head and neck, and cervix [13-16].
The aim of this study was to determine disease-free sur-
vival (DFS), pathologic complete response (pCR) and
associated factors using a multimodal therapy (neoadju-
vant chemotherapy followed by concurrent CCRTh, sur-
gery, and CT) in patients with locally advanced breast
cancer.
Methods
Patients and samples
From January 2000 to December 2003, patients seen at
the INCan Department of Breast Tumors with diagnosis of
breast cancer confirmed by histopathology who presented
loco regional disease (stages IIB, IIIA and -B, according to
the 6th edition of the American Joint Committee on Can-
cer TNM classsification and staging system and evaluated
by thoracic computed tomography (CT) scans, bone scin-
thigraphy and/or PET-CT) [4], without clinical response
(according to the attending physician, based on an
increase in the breast tumor and/or pathologic axillary
lymph node diameters ≥50%) after completion of anthra-
cycline-containing neoadjuvant chemotherapy, and with-
out evidence of distant metastases at diagnosis were
enrolled; this primary CT was followed by concurrent
chemo-radiotherapy (CCRTh), modified radical mastec-
tomy, and adjuvant systemic treatment. Exclusion criteria
comprised other clinical stages from IIB, IIIA, and -B,
Phyllodes tumour as histological diagnosis, and treatment
variations. Biopsies were examined and classified by a
pathologist specialized in this tumor type. The Breast Can-
cer Classification proposed by the World Health Organi-
zation was employed to classify each biopsy. We utilized
the Scarff-Bloom-Richardson (SBR) scale that is based on
nuclear pleomorphism and mitotic count, to stratify each
tumor's tissue differentiation. Hormonal status was
obtained by immunohistochemistry on sections of forma-
lin-fixed, paraffin-embedded tissue, from incisional biop-
sies and subsequent surgical specimens.
Treatment
Neoadjuvant CT was instituted in four 21-days courses.
The following two treatment schedules were utilized: a) 5-
fluorouracil (500 mg/m2), adriamycin (50 mg/m2), and
cyclophosphamide (500 mg/m2) (FAC), or b) adriamycin
(50 mg/m2) and cyclophosphamide (500 mg/m2) (AC).
CCRTh after the previously mentioned regimen was as fol-
lows: RT 60 Gy (3-D CT-based simulation) to the whole-
breast and nodal areas divided into 50 Gy in 5 weeks plus
boost to palpable residual disease with a 10 Gy electron
beam in 1 week, and CT based on mitomycin C (5 mg/
m2), 5-fluorouracil (500 mg/m2), and dexamethasone
(16 mg), or cisplatin (30 mg/m2), gemcitabine (100 mg/
m2) and dexamethasone (16 mg), weekly during RT (six
cycles in total). Radiation Therapy Oncology Group
(RTOG) scale was used for toxicity assessment.
Modified radical mastectomy and axillary lymph-node
dissection were performed post-CCRTh. Six to eight weeks
after surgery, patients received adjuvent systemic treat-
ment with FAC or AC for two additional courses, as previ-
ously described. Patients in another subgroup were
treated with paclitaxel at a dose of 90 mg/m2 weekly for 12
weeks. Adjuvant hormonal treatment was administered to
patients with positive tissue hormonal receptors.
Response
Pathological complete response (pCR) was defined as no
presence of tumor or microscopic disease (presence ofRadiation Oncology 2009, 4:24 http://www.ro-journal.com/content/4/1/24
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microscopic foci in histologic sample) in breast (pCRB)
samples, resected axillary (pCRA) lymph nodes and both
sites (pCR). Pathological response was classified as resid-
ual if any tumour was present.
Statistical analysis
For descriptive purposes, continuous variables were sum-
marized as arithmetic means and standard deviations
(SDs, errors), and categorical variables comprised relative
frequencies and proportions. Inferential comparisons
were performed with the Student t test or the Mann-Whit-
ney U test according to the distribution (normal and non-
normal) determined by the Kolmogorov-Smirnov test.
The Chi-squared or Fisher exact test was utilized to com-
pare clinical variables and pCR. Logistical regression anal-
ysis was employed in significant (or near significant; p =
0.1) variables. Disease-free (DFS) and overall survivals
(OS) were analyzed with the Kaplan-Meier technique, and
comparisons among subgroups were performed with a
log-rank test. All variables were dichotomized for survival
analysis. Adjustment of potential confounders was con-
ducted by log-rank analysis stratification and by Cox pro-
portional hazards regression multivariate analysis. All
tests were two-sided, and the significance value was set at
p = 0.05. SPSS (version 10.0; SPSS, Inc., Chicago, IL, USA)
and STATA (StataCorp, College Station, TX) software
packages were employed for data analysis.
Results
Patients and Samples
Between January 2000 and December 2003, 112 patients
met the selection criteria for this study. Mean age was 50
± 11 years, and median tumour size was 5 ± 1.56 cm.
Patients with tumor at stages T2, -3 and -4 represented
19.6, 44.6 and 35.7% of cases, respectively. Thus, patients
were in clinical stages IIB, IIIA, and -B were 21.4, 42.9, and
35.7%, respectively (Table 1). All neoplasms were infil-
trating ductal carcinoma. ER-positive expression was
found in 42.9%, and in 41.1% for PgR. Low/moderate
histological grade was 40.2, while and high grade stood at
59.8%. Human epithelial growth factor receptor 2
(HER2) expression was not included in data analysis
because only two patients (1.7%) were positive. Post-sur-
gical systemic treatment was based on anthracycline in
48.2% and on taxane drugs in 51.8% of patients (Table 1).
Pathological Complete Response
Pathological response was independently assessed in the
primary site and in the axillary lymph nodes. In the breast,
pCRB was present in 42% (95% Confidence interval [95%
CI], 33.2–50.5), microscopic disease in 27.7% (95% CI,
19.2–36.8), and residual disease in 30.4% (95% CI, 25.3–
38.9) of patients, while in the axilla, pCRA was found in
58% (95% CI, 52.8–65.1) and persistent disease in 42%
(95% CI, 30.2–47.3) of patients. At both sites (breast and
axilla), pCR was 29.5% (95% CI, 21.4–37.5) (Table 2).
Table 3 shows the relationship between pCR and clinico-
pathological factors. Multivariable analysis demonstrated
that the main determinant of pCR was negative ER status
(HR = 3.8; 95% CI, 1.5–9; p = 0.016).
Outcomes
Mean follow-up was 43 months (range 7–125 months).
Median DSF has not been achieved. Five-year DFS was
76.9% (95% CI, 68.2–84.7%). No relationship between
pCR and DFS was found. As independent factors, clinical
stages IIB and IIIA were associated with a longer disease-
free survival (HR = 3.1; 95% CI, 1.02–9.74; p = 0.04) as
compared to clinical stage IIIB (Table 4). Only one patient
had local recurrence. Tumor relapse occurred in 12.5, 3.6,
Table 1: Baseline patient characteristics
Variable
N = 112
Median ± SE Number
(%)
Age (years) 50 ± 11
Tumor size
(cm)
5 ± 1.56
Mean, 3.93
Clinical T stage*
T2 22 (19.6)
T3 50 (44.6)
T4 40 (35.7)
Clinical N stage*
N1 55 (49.1)
N2 56 (50)
N3 1 (0.9)
Clinical stage*
IIB 24 (21.4)
IIIA 48 (42.9)
IIIB 40 (35.7)
Histological grade†
Low/moderate 45 (40.2)
High 67 (59.8)
Estrogen receptors
Positive 48 (42.9)
Negative 64 (57.1)
Progesterone receptors
Positive 46 (41.1)
Negative 66 (58.9)
Treatment after CCRTh
Anthracycline 54 (48.2)
Taxanes 58 (51.8)
Abbreviations: SE = standard error; CCRTh = concurrent chemo-
radiotherapy.
* 6th edition of the American Joint Committee on Cancer TNM 
classification
and staging system.
† Scarff-Bloom-Richardson (SBR) scale.Radiation Oncology 2009, 4:24 http://www.ro-journal.com/content/4/1/24
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2.7, and 1.8% as bone, lung, liver and brain metastasis,
respectively. Three patients had more than one recurrence
site. OS at 5 years was 84.2% (95% CI, 75–93.2%). Toxic-
ity exhibited during CCRTh was as follows: grade 1–2 neu-
tropenia in 32.2%, grade 1–2 anemia in 5.2%, and grade
3 radioepithelitis in 22.4% of patients.
Discussion
Use of neoadjuvant systemic CT and post-mastectomy RT
has become standard for patients with LABC because this
treatment course improves prognosis substantially and
enhances the possibility of surgery [7,17,18]. Advances in
neoadjuvant systemic CT for LABC include not only ear-
lier treatment of sub-clinical distant micrometastases and
primary-tumour downstaging, but also the possibility of
in vivo assessment of response to specific systemic agents.
Thus, it is not only rational, but also current practice, to
apply this approach in inoperable LABC [19]. However,
the magnitude of benefit from neoadjuvant CT on sur-
vival in breast cancer remains unclear due to the few com-
parative trials conducted specifically on LABC [19].
Comparative trials of neoadjuvant vs. adjuvant CT in pri-
mary operable breast cancer demonstrate equivalent sur-
vival outcomes [7]. Despite multimodal therapy
improvements in LABC, 11–30% of patients develop local
relapse [5,20]. Moreover, poor reponse to neoadjuvant CT
is known to be associated with a higher probability of
loco-regional recurrence (LRR) [20]. In our study, no
patient responded to neoadjuvant CT; thus, patients pre-
sented a high risk for LRR. Additionally, approximately
60% were ER-negative, which represents an additional
Table 2: Frequency of pathological-complete response at 
primary site and axilla
Primary site/axilla
N = 112
Frequency
(%)
Negative/negative 29.5
Negative/positive 12.5
Positive/negative 28.6
Positive/positive 29.5
Table 3: Relationship between pathological-complete response at breast and axilla with clinico-pathological factors
Variable
N = 112
pCR
% (95% CI)
Univariate analysis
p
Multivariate analysis
HR (95% CI)
p
Age (years) 0.204
>50 64 (54–74)
<50 75 (67–83)
Clinical T stage* 0.218
T2 54 (45–62)
T3 72 (64–80)
T4 75 (67–83)
Clinical N stage* 0.072
N1 59(51–67)
N2/N3 78 (70–85)
Clinical stage* 0.656
IIB 66 (58–74)
IIIA 66 (58–74)
IIIB 75 (67–83)
Estrogen receptors 0.002 3.8 (0.149–0.087) 0.016
Negative 81 (74–88)
Positive 54 (45–63)
Progesterone receptors 0.090 1.1 (0.391–3.571) 0.767
Negative 75 (67–83)
Positive 60 (52–68)
Histological grade† 0.06 0.5 (0.244–1.038,) 0.063
Low/moderate 60 (52–68)
High 76 (68–84)
Abbreviations: pCR = pathological complete response; 95% CI = 95% confidence interval; HR = hazard ratio.
* 6th edition of the American Joint Committee on Cancer TNM classification and staging system.
† Scarff-Bloom-Richardson (SBR) scale.Radiation Oncology 2009, 4:24 http://www.ro-journal.com/content/4/1/24
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risk factor for patients with LRR in LABC treated with neo-
adjuvant chemotherapy, mastectomy, and RT [20].
Clinical trials regarding the role and benefit of RT in the
management of patients with LABC are sparse. The lim-
ited data and guidelines available do suggest that loco-
regional RT should be employed in post-mastectomy
LABC to reduce LRR rates [17,18,21,22]. We administered
first neoadjuvant chemotherapy, because it is the standard
treatment for LABC. Nevertheless, all included patients
did not present clinical response, thus we proposed
CCRTh. We employed two regimens of CCRTh. The first
was based on 5-FU and mitomycin C, because of previ-
ously good reported results with this treatment in patients
with anal carcinoma [23]. The second regimen was based
on cisplatin and gemcitabine, because of good results
with this multimodal treatment in head and neck carci-
noma and cervical cancer reported in our Institution
[24,25]. Moreover, we added dexamethasone to these two
regimens as an antiemetic drug, and to reduce the risk of
radiation neumonitis. Despite the recent knowledge of
the higher radiation-neumonitis frequency in patients
with lung cancer treated with radiotherapy combined
with gemcitabine [26,27], none of enrolled patients
developed severe lung or cardiac toxicity as late effects.
Moreover, a phase I study showed a reduction of local
recurrence rate with the addition of gemcitabine to chem-
otherapy in unresectable chest wall recurrences [28].
Many issues remain unclear, such as best timing for radi-
otherapy in relation to surgery. We added CCRTh to
standard anthracycline-based chemotherapy to improve
local control in this group of patients, obtaining a 5-years
DFS of 76.9% and only one LRR among these 112 patients
(1%). RT as pre-operative or unique modality has been
described for some time with variable outcomes and
reports of 5-year clinical cure in different breast-cancer
clinical stages [29-31]. In another retrospective study, pre-
operative RT was administered to 75 patients with tumors
>3 cm and only 12% developed LRR, nearly all patients
(96%) underwent conservative surgery with satisfactory
cosmetic results [30]. In contrast, in the present study the
Table 4: Relationship between disease-free survival with clinico-pathological factors
Variable
N = 112
1-year DFS
(months ± SD)
2-year DFS
(months ± SD)
5-year DFS
(months ± SD)
Univariate analysis
p
Multivariate analysis
HR (95% CI)
p
Age (years) 0.09
>50 92 ± 3 82 ± 5 82 ± 5
<50 96 ± 2 94 ± 2 92 ± 3
Clinical T stage* 0.05
T2 90 ± 6 86 ± 7 86 ± 7
T3 98 ± 2 96 ± 2 96 ± 2
T4 87 ± 5 82 ± 6 78 ± 6
Clinical N stage* 0.79
N1 92 ± 3 90 ± 4 90 ± 4
N2/N3 92 ± 3 87 ± 4 84 ± 5
Clinical stage* 0.03 3.1 (1.02–9.74,) 0.0406
IIB/IIIA 95 ± 2 93 ± 3 93 ± 3
IIIB 87 ± 5 82 ± 6 78 ± 6
Estrogen receptors 0.012 0.3 (0.91–1.22,) 0.97
Negative 92 ± 3 85 ± 4 83 ± 4
Positive 97 ± 2 93 ± 3 93 ± 3
Histological grade† 0.04 3.5 (0.79–16.28,) 0.98
Low/moderate 100 97 ± 2 94 ± 3
High 91 ± 3 83 ± 4 83 ± 4
Pathological response 0.56
pCR/microscopic 92 ± 3 88 ± 3 86 ± 4
Residual 94 ± 4 91 ± 4 91 ± 4
Abbreviations: DFS = disease-free survival; SD = standard deviation; HR = Hazard ratio; 95% CI = 95% confidence interval.
* 6th edition of the American Joint Committee on Cancer TNM classification and staging system.
† Scarff-Bloom-Richardson (SBR) scale.Radiation Oncology 2009, 4:24 http://www.ro-journal.com/content/4/1/24
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all patients underwent mastectomy, which likely contrib-
uted to the lower LRR (1%) observed in this study.
There are few reports of CCRTh in LABC. Additional expe-
rience in treatment type is available for early stage breast
carcinoma [31-33]. A retrospective study analyzed 38
patients from five institutional trials with inoperable loco-
regional disease after primary chemotherapy completion
and pre-operative RT treatment, reporting a 5-years DFS of
only 35% and a 5-year LRR of 27% for surgically treated
patients. In our study we report longer survival and pro-
gression-free rates among a larger cohort of patients. Dif-
ferences between our results and those of the previously
mentioned study could be due to differences in the
patient populations (our study did not include stage IV
patients, while 24% of patient in the other study had N3
disease) and our use of CCRTh with radiosensitizing
agents (mitomycin C (5 mg/m2), 5-fluorouracil (500 mg/
m2), and dexamethasone (16 mg) or cisplatin (30 mg/
m2), gemcitabine (100 mg/m2), and dexamethasone (16
mg) weekly for six total courses) during RT.
The success of RT depends on increasing malignant-cell
sensitivity to radiation-induced cell kill coupled with a
reduction in metastasis phenotypes of these cells. Radia-
tion damage to cells and tissues involve generation of
reactive oxygen species and reactive nitrogen species fol-
lowed by alterations in lipids, DNA, and proteins, which
eventually lead to cellular dysfunction or cell death. Alter-
ations in lipid membrane due to peroxidative damage
may form a potential initiator of radiosensitizing effects
in combination with drugs acting through modulation of
membrane associated events involved in apoptosis induc-
tion and increasing oxidative damage or by synchronizing
cells to a radiosensitive phase of the cell cycle thus causing
enhanced killing [34]. This is the rationale for utilizing
radiosensitizing agents, and could explain the good path-
ological response and LRR rates of our study. Nonetheless,
this treatment type could increase toxicity as a result of cell
damage and apoptosis, but this event was presented in our
study patients with the following acceptable profile: grade
1–2 neutropenia in 32.2%; grade 1–2 anemia in 5.2%,
and grade 3 radioepithelitis in 22.4% of patients. This tox-
icity is consistent with other retrospective analyses on
CCRTh, but in patients with early breast carcinoma
[32,33]. For example, a retrospective analysis of 106
patients with early disease treated with CCRTh after breast
conservative surgery (adjuvant CCRTh) reported grade 3
radioepithelitis in 20% of patients. Furthermore, when
authors compared sequential CT and RT with CCRTh, the
latter treatment was superior for 10-year local control (92
vs. 83%); however, in this report there were at least four
different CCRTh schedules; therefore, it is difficult to con-
clude which of the four comprises the better treatment
regime [33]. Another retrospective study compared 485
patients treated with conservative surgery and post-opera-
tive RT with or without concurrent CT, and reported at
multivariate analysis that the CCRTh group exhibited a
statistically lower recurrence rate with significantly higher
grade 2 acute skin toxicity in the concurrent group (21.2
vs. 11.2% of the RT-only group; p < 0.0001) [32]. A phase
III study compared concurrent or sequential adjuvant CRT
after conservative surgery for early-stage breast cancer,
reporting no significant difference for DFS or LRR-free sur-
vival; nevertheless in the node-positive subgroup, the 5-
year LRR-free survival was statistically better in the concur-
rent arm (97% in concurrent vs. 91% in sequential; p =
0.02) corresponding 39% decreased risk for LRR [35].
In our study, on multivariate analysis, ER negative tumors
were associated with higher pCR rates, and poorly differ-
entiated tumors showed a trend for higher pCR rates. A
study of 399 pre-operative CT-treated patients with LABC
reported that negative ER- and PgR expression and grade
3 are associated with high pCR rates [36]. Two other stud-
ies reported similar results concerning the association of
absent hormonal receptors (12 times more likely to
achieve a pCR) and high histological grade with major
pCR rate to neoadjuvant CT in patients with LABC [9,37].
Response rates of neoadjuvant CT in LABC are between 5
and 8.7% with anthracycline-based CT, taxane-containing
regimens, or navelbine-containing regimens [9,37,38]. In
our study, using CCRTh, we found superior pRCB (42%)
and pCR (29.5%) than in other series. A phase II study
reported similar results to ours, for example, a 27% pCR
rate employing pre-operative CCRTh for breast cancer, in
which CT was based on 5-FU and vinorelbine regimens.
Therefore, similar to our results, these authors found three
pCR-associated factors: histological grade 3; absence of
hormonal receptors, and high mitotic index [39]. Tumour
response to pre-operative CT correlates with outcomes
and could identify patients with CT-sensitive micrometas-
tases [7]. We found no association between pCR and DFS.
A possible explanation is that tumor response to CCRTh
does not reflect sensitivity systemically, but only locally.
A previous report clearly describes the surgical complica-
tions of CCRTh-treated patients at our Institution. Three
hundred sixty patients were enrolled in this report, of
whom 46% developed wound complications, 17% surgi-
cal site infection, and 16.9% developed necrosis. The
authors found that radiotherapy-induced skin toxicity
comprises a risk factor for development of major wound
complications. These elevated wound complications may
be explained by radiotherapy effects on tissue healing,
decrease of vascularity, and induction of tissue-hypoxia
and fibrosis, producing necrosis and ulceration [3]. In our
analysis, we only included 112 of these 360 patients,
because they achieved selection criteria for our analysis.
Despite that our series has the larger reported number of
CCRTh-treated patients and that treatment was homoge-
neous (only two regimens of radiosensitizing CT), itRadiation Oncology 2009, 4:24 http://www.ro-journal.com/content/4/1/24
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entertains the limitation of being a retrospective analysis
and patient selection was based on clinical response
according to the attending physician. Notwithstanding
this, we describe valuable information regarding the
CCRTh effect and toxicity in patients with high recurrence
risk.
Conclusion
In summary, our results suggest that CCRTh following
neoadjuvant chemotherapy possesses good local control
with an acceptable toxicity profile, despite the poorer
prognosis of patients with inoperable disease after pri-
mary chemotherapy in LABC. However, a prospective
study needs to be developed to evaluate chemotherapy
effectiveness followed by concomitant chemoradiother-
apy as induction in the group of patients with high recur-
rence risk.
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